StemCell Therapeutics is a Canadian microcap with interesting immuno-oncology programs, in particular the anti-CD47 program. This is a hot field, but this company acquired much of its pipe through an acquisition of Trillium Therapeutics in April of 2013, probably via reverse split transformation from some defunct mining company shell, but I haven't looked. Everything is preclinical or Phase 1 at this point, and since it is a penny stock, it is subject to a) nasty financing deals, and b) slow movement in certain programs.
Its pipe can be seen here: Pipeline
The website doesn't provide much in the way of links to publications or IP, so we'll have to do that digging on our own. |
